Latest News
Protagonist Therapeutics, Inc.
- Protagonist Therapeutics (PTGX) Wins FDA Nod for MIMRYLO and a $275 Million Milestone
- Form 4 Protagonist Therapeutics Inc: Asif Ali (CFO) For: 30 September
- Protagonist Therapeutics (PTGX) Stock May Look Fully Priced On Earnings
- Johnson & Johnson and Protagonist Therapeutics Icotyde: The Best Inventions of 2026
- Protagonist Therapeutics (PTGX) Could Be 21% Undervalued As Royalty Funded Narrative Builds
- UBS sets USD 184.00 target for Protagonist Therapeutics stock
- Nektar, Protagonist, Shattuck are Leerink top picks in emerging immunology
- UBS initiates Protagonist Therapeutics stock with buy rating on drug potential
- Protagonist Therapeutics (NASDAQ:PTGX): High Growth Momentum Meets Breakout Setup
- Protagonist Therapeutics stock gains 1.47 percent on Nasdaq 2026-10-05
- Protagonist Therapeutics stock gets USD 300.0 million buyback approval
- Here's How Much $100 Invested In Protagonist Therapeutics 10 Years Ago Would Be Worth Today
Headlines from the last 30 days, linking to the original publishers. See all market news →